Home > Boards > US OTC > Basic Materials > Bioxytran Inc. (BIXT)

BIXT is starting to gain higher awareness and

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ProfitScout Member Profile
 
Followed By 123
Posts 14,180
Boards Moderated 11
Alias Born 04/03/02
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/31/2020 2:35:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/15/2020 4:01:11 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 1/10/2020 2:40:23 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 1/6/2020 4:27:12 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 12/11/2019 7:53:53 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/25/2019 5:09:27 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/13/2019 1:20:05 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 3:09:24 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 11/5/2019 3:36:26 PM
Small Company Offering and Sale of Securities Without Registration (d) Edgar (US Regulatory) - 11/5/2019 1:51:26 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/28/2019 9:14:38 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 2:57:37 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/9/2019 3:55:21 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 3:33:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/12/2019 9:03:15 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 5/30/2019 9:51:25 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 5/30/2019 9:49:39 AM
Statement of Beneficial Ownership (sc 13d) Edgar (US Regulatory) - 5/30/2019 9:47:09 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/29/2019 1:30:50 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/10/2019 2:47:11 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/6/2019 9:40:40 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/26/2019 5:23:31 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/5/2019 4:26:45 PM
Annual Report (10-k) Edgar (US Regulatory) - 3/13/2019 6:25:14 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/1/2019 10:09:20 AM
ProfitScout   Tuesday, 05/21/19 12:26:28 PM
Re: jedijazz post# 454
Post # of 505 
BIXT is starting to gain higher awareness and recognition for the valuable advances this company is making to save lives in critical situations that involve oxygen delivery to vital organs. I expect to see increasing appreciation for this stock as more medical institutions begin incorporating the valuable contributions from BIXT.

Bioxytran Inc. is a developmental stage biotechnology company. The company is working towards a first-in-class oxygen treatment platform for victims of brain stroke trauma. The first product to proceed to testing is BXT-25, which will be evaluated as a resuscitative agent to treat strokes, especially during the all-critical first hour following a stroke. The product will also be evaluated for its efficacy in treating other brain trauma issues. BXT-25 is based on a new molecule designed to reverse hypoxia in the brain. Hypoxic brain injuries such as ischemic strokes, could be treated with BXT-25 via an intravenous injection that quickly allows the drug molecule to travel to the lungs and bind with the oxygen molecules. From the lungs the molecule mimics a red blood cell traveling to the brain. Since the molecule is 5,000 times smaller than red blood cells it can penetrate the clot and deliver the oxygen to the critical areas in the brain blocked by the clot. The MDX Viewer will be used in evaluation of the safety and efficacy of the BXT-25. To learn more, visit our website: www.Bioxytraninc.com

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist